Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience Journal Article


Authors: Motzer, R. J.; Bacik, J.; Mazumdar, M.
Article Title: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience
Abstract: Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon a as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.
Journal Title: Clinical Cancer Research
Volume: 10
Issue: 18
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2004-09-15
Start Page: 6302S
End Page: 6303S
Language: English
ACCESSION: WOS:000224080600005
DOI: 10.1158/1078-0432.ccr-040031
PROVIDER: wos
PUBMED: 15448021
Notes: Article; Proceedings Paper -- 1st International Conference on Innovations and Challenges in Renal Cancer -- MAR 19-20, 2004 -- Cambridge, MA -- S -- 2 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Madhu Mazumdar
    127 Mazumdar
  3. Jennifer M Bacik
    46 Bacik